CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $10.68M, lower than 95% of all stocks globally
- PositionCurrent ratio is 22.13×, higher than 95% of its Biotechnology peers (median 5.5×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.34BUSDvs all stocks (USD)
Revenue (TTM)
10.68MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.68xvs all stocks
52-Week Change
448.49%vs all stocks
Market Capitalization
4.34BUSDvs all stocks (USD)
Enterprise Value
3.20BUSDvs all stocks (USD)
Forward P/E
-12.14xvs Biotechnology peers
Price to Book (MRQ)
5.87xvs Biotechnology peers
Enterprise to Revenue
300.11xvs Biotechnology peers
Enterprise to EBITDA
-10.91xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-2619.67%vs Biotechnology peers
Return on Assets (TTM)
-24.72%vs Biotechnology peers
Return on Equity (TTM)
-40.01%vs Biotechnology peers
Revenue (TTM)
10.68MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0610USDUpdated Jul 19, 2026Quarterly Revenue Growth
-60.90%vs Biotechnology peers
Gross Profit (TTM)
-245.58MUSDvs all stocks (USD)
EBITDA (TTM)
-293.61MUSDvs all stocks (USD)
Net Income (TTM)
-272.70MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-60.93%vs Biotechnology peers
Operating Cash Flow (TTM)
-213.36MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-121.18MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
15.36MUSDFY2025 · Dec 31, 2025Operating Income
-302.74MUSDvs all stocks (USD)
Pre-tax Income
-276.48MUSDFY2025 · Dec 31, 2025Net Income
-276.48MUSDFY2025 · Dec 31, 2025EBIT
-302.74MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-299.18MUSDFY2025 · Dec 31, 2025Research & Development
261.38MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
56.71MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
27.04MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-276.48MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-223.98MUSDFY2025 · Dec 31, 2025Free Cash Flow
-224.39MUSDDerived from operating cash flow minus capital expenditure. This filing charges 3.56M of depreciation against 410K of capital expenditure, and its own free-cash-flow line reads -235.87M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
85.35MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-276.48MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
3.56MUSDFY2025 · Dec 31, 2025Stock-based Compensation
62.42MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-13.48MUSDFY2025 · Dec 31, 2025Capital Expenditures
-410.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-122.97MUSDFY2025 · Dec 31, 2025Sale of Investments
316.18MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
192.80MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
0.00USDFY2025 · Dec 31, 2025Shares Outstanding
189.21MSharesUpdated Jul 19, 2026Float Shares
136.14MSharesUpdated Jul 19, 2026Shares Short
43.04MSharesUpdated Jul 19, 2026Short Ratio
8.72daysvs all stocks
Short % of Shares Outstanding
23.02%vs all stocks
% Held by Insiders
1.37%vs all stocks
% Held by Institutions
87.18%vs all stocks
Total Cash (MRQ)
642.07MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.35USDUpdated Jul 19, 2026Total Debt (MRQ)
31.57MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0492xvs Biotechnology peers
Current Ratio (MRQ)
22.13xvs Biotechnology peers
Book Value per Share (MRQ)
3.39USDUpdated Jul 19, 2026Total Assets
621.33MUSDvs all stocks (USD)
Total Current Assets
578.28MUSDFY2025 · Dec 31, 2025Total Liabilities
54.27MUSDFY2025 · Dec 31, 2025Total Non-current Assets
43.05MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
28.69MUSDFY2025 · Dec 31, 2025Total Current Liabilities
25.58MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
84.02MUSDFY2025 · Dec 31, 2025Other Short-term Investments
470.50MUSDFY2025 · Dec 31, 2025Accounts Payable
7.71MUSDFY2025 · Dec 31, 2025Short-term Debt
3.77MUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Other Current Liabilities
463.00KUSDFY2025 · Dec 31, 2025Long-term Debt
28.69MUSDFY2025 · Dec 31, 2025Common Stock (Book)
168.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-2.01BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
567.06MUSDvs all stocks (USD)
52-Week Low
3.02USDUpdated Jul 19, 202652-Week High
20.79USDUpdated Jul 19, 202652-Week Change
448.49%vs all stocks
Beta
1.68xvs all stocks
50-Day MA
15.76USDUpdated Jul 19, 2026200-Day MA
10.70USDUpdated Jul 19, 2026Avg 10-Day Volume
3.16MSharesUpdated Jul 19, 2026Avg 30-Day Volume
4.14MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.56USDUpdated Jul 19, 2026Other Income / Expense
-776.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Low-Leverage Liquidity Configuration
Cash on hand covers most or all of its debt, and its equity share of assets is high for its industry.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 22.13×, higher than 95% of its Biotechnology peers (median 5.5×)Significant
Current ratio: 22.13Industry median: 5.50Industry P95: 22.03Peers compared: 197
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $10.68M, lower than 95% of all stocks globallySignificant
Revenue (USD): 10,676,000Global P5: 30,274,777.221
Market cap is $4.34B, above the global median of $1.15BNotable
Market cap (USD): 4,339,192,010Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Humanwell Healthcare Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Celcuity Inc.
Tier 1ProductionApproval-Gated PipelineRule
Viking Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chongqing Zhifei Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Acadia Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Edgewise Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
LivaNova PLC
Tier 1ProductionApproval-Gated PipelineRuleRisk
Simcere Pharmaceutical Group Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xuanzhu Biopharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Erasca, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Oruka Therapeutics, Inc.
1 interpretationLow-Leverage Liquidity Configuration
Iovance Biotherapeutics, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity